Pharma BD Deal Intelligence
UK pharma mega-merger delivered synergies but struggled with R&D productivity
Full analysis, sources & comparables →Ranks computed across 828 graded deals (Critic + Outcome Score both present).
Merger of Glaxo Wellcome and SmithKline Beecham creates pharmaceutical giant. The proposed merger was valued at $76 billion and was expected to give the…
Glaxo Wellcome and SmithKline Beecham announced their merger on January 17, 2000, creating the worlds largest drug company with combined annual sales of…
The twenty-first centurys first mega merger formed GlaxoSmithKline through the combination of Glaxo Wellcome and SmithKline Beecham, with $25 billion in sales…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Glaxo Wellcome plc and SmithKline Beecham plc merged on January 17, 2000 in a stock-for-stock merger of equals valued at approximately $76 billion, closing December 27, 2000 to form GlaxoSmithKline plc — at the time the world's largest pharmaceutical company with combined revenues of ~$25 billion and the sector's largest R&D budget. Glaxo Wellcome shareholders received ~58.75% of the combined entity; SmithKline Beecham shareholders ~41.25%. The combined franchise anchored #1 or #2 global leadership in HIV/antivirals (Combivir, Ziagen, Trizivir), vaccines (Engerix-B, Infanrix, Havrix, Varilrix), respiratory (Seretide/Advair, Ventolin, Flovent), antibiotics (Augmentin), CNS (Paxil/Seroxat, Wellbutrin), and OTC consumer health (Panadol, Tums, Aquafresh). Jean-Pierre Garnier (ex-SKB) became CEO; Sir Richard Sykes (ex-Glaxo) became non-executive chairman. The merger established the template for the large-pharma consolidation wave of the 2000s (Pfizer/Warner-Lambert, Pfizer/Pharmacia, Sanofi/Aventis).
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Glaxo Wellcome plc / SmithKline Beecham (this deal) | 2000 | $76.0B | 64 |
| Pfizer Inc. / BioNTech SE | 2020 | $748M | 100 |
| Gilead Sciences Inc. / Pharmasset Inc. | 2011 | $11.2B | 98 |
| Abbott Laboratories / Alere Inc. | 2016 | $5.8B | 95 |
| bioMerieux SA / BioFire Diagnostics Inc. | 2013 | $485M | 88 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2008 | $3.4B | 88 |
| AstraZeneca PLC / MedImmune Inc. | 2007 | $15.6B | 82 |
← Browse all deals · How we score deals
More: 2000 deals · Infectious Disease deals